FBR & Co reissued their outperform rating on shares of Prima BioMed Ltd. (NASDAQ:PBMD) in a report issued on Friday. The firm currently has a $6.00 price target on the stock.
Immutep Ltd. buy Quitte
Start price
21.07.16
/
50%
€0.15
Target price
23.01.17
€0.20
Performance (%)
-13.33%
End price
23.01.17
€0.13
Summary
This prediction ended on 23.01.17 with a price of €0.13. The price of Immutep Ltd. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -13.33%. Quitte has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Immutep Ltd. | 3.922% | 3.922% | -81.206% | -83.742% |
| iShares Core DAX® | 0.437% | 5.897% | 8.047% | 65.579% |
| iShares Nasdaq 100 | 1.057% | 0.920% | 28.466% | 90.185% |
| iShares Nikkei 225® | 1.769% | 1.228% | 47.574% | 84.991% |
| iShares S&P 500 | 0.368% | 1.920% | 23.200% | 70.760% |
Comments by Quitte for this prediction
In the thread Immutep Ltd. diskutieren
wer wagt ....
(Laufzeit überschritten)